<?xml version="1.0" encoding="UTF-8"?>
<p>The risks of nose and throat swabs and additional blood tests being taken are minimal and where occurring are likely to be mild. No additional adverse events s related to POCT for respiratory viruses are anticipated. However active monitoring and reporting of severe adverse events will be undertaken. Serious adverse events (SAE) are defined here as:
 <list list-type="bullet">
  <list-item>
   <p>Death during admission or within 30Â days of enrolment</p>
  </list-item>
  <list-item>
   <p>Admission to the intensive care unit</p>
  </list-item>
  <list-item>
   <p>Evidence of prolonged hospital stay</p>
  </list-item>
  <list-item>
   <p>New or persistent significant disability or incapacity</p>
  </list-item>
  <list-item>
   <p>Evidence of congenital anomaly or birth defect</p>
  </list-item>
 </list>
</p>
